{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T01:40:18Z","timestamp":1789609218049,"version":"build-2803163510"},"reference-count":23,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","trasci.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion and Apheresis Science"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.transci.2016.09.017","type":"journal-article","created":{"date-parts":[[2016,10,5]],"date-time":"2016-10-05T03:01:44Z","timestamp":1475636504000},"page":"357-362","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Efficacy and safety of eculizumab in adult patients with atypical hemolytic uremic syndrome: A single center experience from Turkey"],"prefix":"10.1016","volume":"55","author":[{"given":"Fusun","family":"Gediz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahriye Kadriye","family":"Payzin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sertac","family":"Ecemis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naile","family":"G\u00fcler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asu Fergun","family":"Yilmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fusun","family":"Topcugil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afig","family":"Berdeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.transci.2016.09.017_bib0010","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1097\/MOH.0b013e32833cae86","article-title":"Atypical hemolytic uremic syndrome","volume":"17","author":"Kavanagh","year":"2010","journal-title":"Curr Opin Hematol"},{"issue":"2","key":"10.1016\/j.transci.2016.09.017_bib0015","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1182\/blood-2009-05-221549","article-title":"Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome","volume":"115","author":"Moore","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.transci.2016.09.017_bib0020","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/1750-1172-6-60","article-title":"Atypical hemolytic uremic syndrome","volume":"6","author":"Loirat","year":"2011","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.transci.2016.09.017_bib0025","first-page":"3","article-title":"Atypical hemolytic uremic syndrome (aHUS): making the diagnosis","volume":"10","author":"Laurence","year":"2012","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1016\/j.transci.2016.09.017_bib0030","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/nrneph.2012.195","article-title":"STEC-HUS, atypical HUS and TTP are all diseases of complement activation","volume":"8","author":"Noris","year":"2012","journal-title":"Nat Rev Nephrol"},{"issue":"4","key":"10.1016\/j.transci.2016.09.017_bib0035","doi-asserted-by":"crossref","first-page":"554","DOI":"10.2215\/CJN.04760512","article-title":"Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults","volume":"8","author":"Fremeaux-Bacchi","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"10.1016\/j.transci.2016.09.017_bib0040","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.semnephrol.2013.08.003","article-title":"Atypical hemolytic uremic syndrome","volume":"33","author":"Kavanagh","year":"2013","journal-title":"Semin Nephrol"},{"issue":"5","key":"10.1016\/j.transci.2016.09.017_bib0045","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1056\/NEJMc0808527","article-title":"Eculizumab for atypical hemolytic-uremic syndrome","volume":"360","author":"N\u00fcrnberger","year":"2009","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.transci.2016.09.017_bib0050","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1055\/s-0030-1262889","article-title":"New treatment options for atypical hemolytic uremic syndrome with the complement inhibitor eculizumab","volume":"36","author":"K\u00f6se","year":"2010","journal-title":"Semin Thromb Hemost"},{"issue":"8","key":"10.1016\/j.transci.2016.09.017_bib0055","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.2215\/CJN.01090209","article-title":"Complement inhibitor eculizumab in atypical hemolytic uremic syndrome","volume":"4","author":"Mache","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.transci.2016.09.017_bib0060","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/1477-7525-1-79","article-title":"The functional assessment of chronic illness therapy (FACIT) measurement system: properties, applications, and interpretation","volume":"1","author":"Webster","year":"2003","journal-title":"Health Qual Life Outcomes"},{"issue":"6","key":"10.1016\/j.transci.2016.09.017_bib0065","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-Item short-form health survey (SF-36). I. Conceptual framework and item selection","volume":"30","author":"Ware","year":"1992","journal-title":"Med Care"},{"key":"10.1016\/j.transci.2016.09.017_bib0070","series-title":"Soliris\u00ae (eculizumab) [prescribing information]","author":"US Food and Drug Administration","year":"2014"},{"issue":"3","key":"10.1016\/j.transci.2016.09.017_bib0075","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.kint.2015.11.026","article-title":"Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome","volume":"89","author":"Greenbaum","year":"2016","journal-title":"Kidney Int"},{"issue":"21","key":"10.1016\/j.transci.2016.09.017_bib0090","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.1182\/blood-2014-09-600411","article-title":"Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS","volume":"125","author":"Cofiell","year":"2015","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.transci.2016.09.017_bib0085","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.transci.2016.09.017_bib0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/295323","article-title":"Eculizumab therapy leads to rapid resolution of thrombocytopenia in atypical hemolytic uremic syndrome","volume":"2014","author":"Tsai","year":"2014","journal-title":"Adv Hematol"},{"issue":"1","key":"10.1016\/j.transci.2016.09.017_bib0105","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1053\/j.ajkd.2013.07.011","article-title":"Fr\u00e9meaux-Bacchi V. Insights from the use in clinical practice of eculizumab in adult patients with atypical hemolytic uremic syndrome affecting the native kidneys: an analysis of 19 cases","volume":"63","author":"Fakhouri","year":"2014","journal-title":"Am J Kidney Dis"},{"issue":"11","key":"10.1016\/j.transci.2016.09.017_bib0110","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2013-003573","article-title":"A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS)","volume":"3","author":"Rathbone","year":"2013","journal-title":"BMJ Open"},{"key":"10.1016\/j.transci.2016.09.017_bib0115","first-page":"39","article-title":"Critical appraisal of eculizumab for atypical hemolytic uremic syndrome","volume":"7","author":"Palma","year":"2016","journal-title":"J Blood Med"},{"issue":"1","key":"10.1016\/j.transci.2016.09.017_bib0120","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1053\/j.ajkd.2015.04.010","article-title":"Discontinuation of eculizumab treatment in atypical hemolytic uremic syndrome: an update","volume":"66","author":"Ardissino","year":"2015","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"10.1016\/j.transci.2016.09.017_bib0125","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1053\/j.ajkd.2014.01.434","article-title":"Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: a report of 10 cases","volume":"64","author":"Ardissino","year":"2014","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"10.1016\/j.transci.2016.09.017_bib0130","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.molimm.2012.12.006","article-title":"Analysis of genetic and predisposing factors in Japanese patients with atypical hemolytic uremic syndrome","volume":"54","author":"Fan","year":"2013","journal-title":"Mol Immunol"}],"container-title":["Transfusion and Apheresis Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050216301409?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050216301409?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,7]],"date-time":"2018-09-07T19:26:31Z","timestamp":1536348391000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1473050216301409"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["S1473050216301409"],"URL":"https:\/\/doi.org\/10.1016\/j.transci.2016.09.017","relation":{},"ISSN":["1473-0502"],"issn-type":[{"value":"1473-0502","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of eculizumab in adult patients with atypical hemolytic uremic syndrome: A single center experience from Turkey","name":"articletitle","label":"Article Title"},{"value":"Transfusion and Apheresis Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transci.2016.09.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}